long intergenic non-protein coding RNA 844Genealiases: []
Q-omics provides the consensus-scored LINC00844 profile across patient tissues and cancer cell-line models. LINC00844 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC00844 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, LINC00844 RNA expression shows 13,143 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, COAD, and GBM as cancer lineages where LINC00844 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00844 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00844 survival associations across molecular data types. LINC00844 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00844 RNA expression–survival associations across cancer types. High LINC00844 expression shows unfavorable associations in THYM, but favorable associations in BRCA, KIRP, LGG, LIHC and ACC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC00844 RNA expression.
This table summarizes LINC00844 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00844. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00844 shows lower tumor expression in COAD, KICH, KIRP, HNSC, LUAD and BLCA. The COAD box plot shows higher LINC00844 RNA expression in normal versus tumor tissue (log2 FC = −0.430, t-test p < 0.001).
This table shows molecular features associated with LINC00844 in patient tissues and cancer cell lines. In patient samples, LINC00844 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
